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CASE REPORT
A 56-year-old African American, former light-smoker 
woman presented with a 3-month history of atypical chest 
pain, dry cough, intermittent night sweats, and 20-pound 
weight loss. Physical examination revealed reproducible pain 
at the right sternal border with clear lung fields and no lymph-
adenopathy. A 1.5 cm nodular opacity in the right mid lung 
was noted on a posteroanterior chest radiograph. Computed 
tomography showed minimal pericardial effusion in addition 
to a 5.5 cm mass extending from the right anterior cardio-
phrenic angle into the chest wall (Fig. 1A), a 1.8 cm mass in 
the lateral segment of the right middle lobe (Fig. 1B), and a 
1.9 cm right pleural-based mass posterior to the inferior vena 
cava. Laboratory evaluation showed anemia of chronic dis-
ease with hemoglobin of 9.7 g/dL, serum alpha-fetoprotein 
of 2.0 ng/mL, and β-hCG less than 2.0 IU/L. Percutaneous 
core needle biopsy of the right chest-wall mass revealed 
large atypical cells with hepatic differentiation (Fig. 2A, B). 
Immunohistochemical staining and molecular profiling results 
(Table 1) included positivity for antibodies to HepPar-1 (Fig. 
2C) and the presence of ALK gene rearrangement.
The patient was started on crizotinib 250 mg orally every 
12 hours, leading to resolution of her symptoms and anemia 
within approximately 2 weeks. Computed tomography scans 
were performed every 2 months, with the first scan showing 
significant reduction in the baseline lesions (Fig. 1C, D). The 
patient discontinued crizotinib for radiologic progression of 
lung disease 6 months after initiation of therapy.
DISCUSSION
The World Health Organization classifies hepatoid 
carcinomas as a subtype of hepatoid adenocarcinoma, first 
described in the stomach as tubular or papillary adenocar-
cinoma with sheets of neoplastic cells resembling hepato-
cellular carcinoma (HCC).1 Hepatoid adenocarcinomas 
often occur in organs arising from the primitive foregut.2 
Histological types other than adenocarcinoma can be associ-
ated with hepatoid differentiation.3 Currently, there are no 
specific tissue markers to differentiate between HCC and 
hepatoid carcinoma. For example, HepPar-1, a sensitive 
marker for HCC, is also commonly expressed by hepatoid 
adenocarcinomas.2
The anaplastic lymphoma kinase tyrosine kinase 
inhibitor crizotinib has shown significant activity in approxi-
mately 5% of non–small-cell lung cancer patients who har-
bor ALK gene rearrangements, with response rates of 61% 
to 83%.4 The response to crizotinib observed in our case is 
important because hepatoid carcinomas have a poor prog-
nosis and are often resistant to chemotherapy. A review of 
14 cases of hepatoid adenocarcinomas of the lung showed a 
median survival of only 4.5 months.2 There are no reported 
cases of hepatoid carcinoma of the lung treated with a tyro-
sine kinase inhibitor. The multikinase inhibitor sorafenib has 
resulted in progression-free survival of 7 months in a patient 
with pancreatic hepatoid carcinoma who died 1 year after 
diagnosis5 and temporary clinical improvement in a patient 
with hepatoid adenocarcinoma in the peritoneal cavity, who 
died 6 months after diagnosis.2
To our knowledge, this case represents the first report 
of ALK gene rearrangement in a patient with hepatoid carci-
noma, suggesting an important role for molecular-profiling–
directed therapy in non–small-cell lung cancer patients with 
rare and aggressive histologies.
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FIGURE 1.  Baseline CT scan showing masses in the (A) anterior chest wall (arrow) and (B) right middle lobe of the lung 
(arrow). After 2 months of therapy with crizotinib, a restaging CT scan showed (C) more than 30% reduction in the chest-wall 
mass (arrow), (D) near-complete resolution of the right middle lobe lung mass (arrow), and approximately 20% reduction in 
the right pleural-based mass (not shown). CT, computed tomography.
TABLE 1. Results of Immnohistochemical Staining and Molecular Profiling Analysis on Patient’s Tumor Tissue
Immunohistochemistry
AE1/AE3, CAM5.2, CK7, CK5/6, HepPar-1, Claudin 4, EMA (cytoplasmic),  
OCT4, CEA, CD10
Positive
Calretinin, WT-1, AFP Equivocal
TTF-1, BHCG, CK20, vimentin, GCDFP-15, p63, CHG, thyroglobulin, RCC Negative
Molecular profiling
EGFR (exons 18–21), KRAS (exons 2, 3), BRAF (exon 15), AKT (exon 1), 
 PIK3CA (exons 9, 20), NRAS (exons 2, 3)
Wild type
HER2 No amplification by FISH (HER2/CEP17 ratio 1.3). Copy number gain 
(4–5 copies per cell) scored in 23 of 50 cells (46%).
ALK Positive rearrangement signal in 179 of 246 nuclei (72.8%) by FISH 
analysis using ALK break apart rearrangement probe.
AFP, alpha-fetoprotein; ALK, anaplastic lymphoma kinase; BHCG, beta-human chorionic gonadotropin; CEA, carcinoembryonic antigen; CEP17, chromosome 17 centromere; 
CHG, chromogranin; CK, cytokeratin; EMA, epithelial membrane antigen; FISH, fluorescent in situ hybridization; GCFP-15, gross cystic disease fluid protein-15; HepPar-1, 
hepatocyte paraffin-1; HER2, epidermal growth factor receptor 2; OCT4, octamer-binding transcription factor 4; TTF-1, thyroid transcription factor-1; WT-1, Wilms’ tumor-1.
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FIGURE 2. A, Romanowski (200×) and (B) hematoxylin and eosin (400×) staining showing large atypical cells with round-to-
oval hyperchromatic nuclei, prominent nucleoli, and moderate-to-abundant dense cytoplasm arranged in trabecular aggregates 
morphologically, suggestive of hepatic differentiation. C, Immunocytochemical analysis of cellblock section with antibodies to 
HepPar-1 (400×) demonstrated a positive granular cytoplasmic staining pattern.
